This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Pfizer (PFE) Q4 Earnings Miss, Sales Beat, 2021 View Upbeat
by Zacks Equity Research
Pfizer (PFE) misses estimates for earnings while beating the same for sales. It provides an upbeat financial outlook for 2021.
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, Abbott Laboratories, Starbucks and Target
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, Abbott Laboratories, Starbucks and Target
Top Research Reports for Netflix, Bristol-Myers & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Bristol-Myers Squibb (BMY), and Abbott Laboratories (ABT).
What's in the Cards for Bristol-Myers' (BMY) Q4 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter 2020 results.
Pfizer's (PFE) Key Brands Likely to Drive Its Q4 Earnings
by Zacks Equity Research
Pfizer's (PFE) Biopharma unit becomes the "New Pfizer" following the separation of the Upjohn unit. The Q4 announcement will the first quarterly result for the "New Pfizer".
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the fourth quarter is what remains to be seen when the company reports results.
Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Moderna (MRNA) and Exelixis (EXEL).
Pfizer's (PFE) Bavencio Gets EU Nod for First-Line Bladder Cancer
by Zacks Equity Research
The European Commission approves Pfizer (PFE) and Merck KGaA's Bavencio as a monotherapy for first-line maintenance treatment in advanced/metastatic urothelial carcinoma.
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $64.83, moving +0.42% from the previous trading session.
Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC
by Zacks Equity Research
Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.
Will Bristol-Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol Myers' (BMY) Opdivo Label Expansion Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review.
AstraZeneca (AZN) Gets EU Nod for Improved Imfinzi Dosing
by Zacks Equity Research
AstraZeneca's (AZN) four-week, fixed-dose regimen (1500 mg) of Imfinzi will reduce patients's medical visits by half, thereby improving patent convenience.
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $66.54, moving +0.79% from the previous trading session.
BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China
by Zacks Equity Research
BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.
Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA
by Zacks Equity Research
Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.
Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag
by Zacks Equity Research
Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $65.43, moving +0.71% from the previous trading session.
bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity
by Zacks Equity Research
bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.
Exelixis (EXEL) Reports Preliminary Q4 Results, Business Updates
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and 2020 along with the annual guidance for 2021. It also throws light on anticipated milestones for 2021.
Infinity (INFI) Provides Data on Eganelisib in Urothelial Cancer
by Zacks Equity Research
Infinity (INFI) provides an update on Eganelisib in patients with metastatic urothelial cancer.
Xencor (XNCR) Inks Deal for Novel Antibody Therapies in Cancer
by Zacks Equity Research
Xencor (XNCR) signs a strategic research collaboration deal with MD Anderson Cancer Center to develop and commercialize T Cell-engaging bispecific antibodies for treating cancer.
Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $61.70, marking a +0.24% move from the previous day.
Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.